RELATED CONTENT
IBA (Ion Beam Applications S.A) has launched its Compass 3.0 plan verification system. Compass, the first patient anatomy-centric and solution for advanced intensity-modulated radiotherapy (IMRT) and rotational plan verification now provides a new two-in-one solution: calculation-based full 3-D independent treatment plan system (TPS) verification and measurement-based quality assurance (QA) for the complete treatment chain, including linear accelerators.
August 09, 2013 
A quality assurance test can be performed within one minute using IBA's MagicMaX QA system for X-ray machines. The ...
February 06, 2013 At RSNA 2012, IBA showcased several quality assurance (QA) solutions for radiology. The MagicMax is an all-in-one QA ...
December 07, 2012 At ASTRO 2012, IBA featured a scale model install of its Proteus One compact proton system combined with the Philips ...
November 20, 2012 
IBA (Ion Beam Applications S.A.) launched the new Visicoil Twin-Line fiducial marker at the annual meeting of the 2012 American Society for Radiation Oncology (ASTRO).
October 31, 2012 
October 30, 2012 — IBA Group, a leader in advanced cancer diagnosis and therapy technologies, and Royal Philips Electronics announced their first installation of a state-of-the-art, patient-centered proton therapy treatment room in the United States.
October 30, 2012 
LXcan is designed to be the ideal solution for QA of image display devices. It features distance and contact measurement ...
October 15, 2012 
August 21, 2012 — IBA (Ion Beam Applications S.A.) officially opened its International Competence Center (ICC) in July in Nuremberg, Germany. The ICC provides high-level practical training to promote safer radiation therapy to healthcare professionals, using the latest software and hardware radiation treatment and specialist measurement tools.
August 21, 2012 IBA Dosimetry offers commissioning services for linear accelerators (linacs), using state-of-the-art equipment like the ...
August 21, 2012 
Proton therapy is a variant of conventional external beam radiation therapy or stereotactic radiosurgery. Whereas traditional radiation therapies use X-ray photons as the “ammunition” to target tumors, proton therapy uses the significantly more massive proton to try to decimate diseased tissues. From a patient benefit standpoint, there’s more to proton therapy than just “bigger bullets” targeting tumors, it is also that the collateral risks to the patient are lower.
May 03, 2012